ARO-MAPT is designed to silence expression of the microtubule-associated protein tau (MAPT) gene in the central nervous system, targeting pathological tau protein aggregation implicated in Alzheimer's disease, frontotemporal dementia, and progressive supranuclear palsy.

From the articleExperimental Arrowhead RNAi drug hints at Alzheimer’s benefitAlso in Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop, Arrowhead reports positive interim data for Alzheimer’s drug By Investing.com